Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Cadila Healthcare...

    Cadila Healthcare posts Q4 net profit of Rs 460 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-30T09:15:13+05:30  |  Updated On 16 Aug 2021 1:06 PM IST

    The consolidated financial statements for the quarter and the year ended March 31, 2019, including the operations of Heinz India Pvt Ltd (HIPL) for the period from January 30, 2019, with provisional purchase price allocation figures, Cadila Healthcare said.


    New Delhi: Cadila Healthcare Wednesday reported a consolidated net profit of Rs 460.1 crore for the quarter ended March 31.


    The drug firm had posted a net profit of Rs 590.8 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a filing to the BSE.


    Its consolidated total revenue from operations stood at Rs 3,732.8 crore for the quarter. It was Rs 3,237.8 crore in the corresponding period a year ago.


    Read Also: Cadila Healthcare gets 14 USFDA observations for Moraiya plant


    The consolidated financial statements for the quarter and the year ended March 31, 2019, including the operations of Heinz India Pvt Ltd (HIPL) for the period from January 30, 2019, with provisional purchase price allocation figures, Cadila Healthcare said.


    "Hence, the figures of the quarter and the year ended March 31, 2019, are not comparable with the figures of the previous periods," it added.


    For the full fiscal year ended March, the company posted a net profit of Rs 1,848.8 crore. It was Rs 1,775.8 crore for the previous fiscal year.


    The company's total revenue from operations for the fiscal year ended March 2019 stood at Rs 13,165.6 crore. It was Rs 11,954.4 crore for the year-ago fiscal year.


    The company said its board has recommended a dividend of Rs 3.50 per equity share on 1,02,37,42,600 equity shares of Re 1 each for the financial year ended on March 31, 2019.


    Read Also: Biocon, Lupin, Wockhardt, Cadila Healthcare lose Insurance Battle in Delhi High Court


    Strengthening its regulatory pipeline, the company filed 29 abbreviated new drug applications (ANDAs) during the year with the USFDA, taking the cumulative filings to 360. The company received 74 ANDA approvals taking the total to 254 product approvals, Cadila Healthcare said.

    abbreviated new drug applicationsANDAsBSECadila Healthcarecadila healthcare financial resultsconsolidated revenuefourth quarter resultsHeinz India Pvt LtdHIPLNew DelhiQ4 resultShares of Cadila HealthcareUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok